Kalvista Pharmaceuticals Inc (KALV) PT Raised to $42 at Stifel

March 25, 2026 4:22 PM

Stifel analyst Paul Matteis raised the price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) to $42.00 (from $39.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found